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Artificial intelligence could alert 
for focal skeleton/bone marrow 
uptake in Hodgkin’s lymphoma 
patients staged with FDG‑PET/CT
May Sadik1*, Jesús López‑Urdaneta1, Johannes Ulén2, Olof Enqvist3, Armin Krupic1, 
Rajender Kumar4, Per‑Ola Andersson5 & Elin Trägårdh6
To develop an artificial intelligence (AI)‑based method for the detection of focal skeleton/bone marrow 
uptake (BMU) in patients with Hodgkin’s lymphoma (HL) undergoing staging with FDG‑PET/CT. 
The results of the AI in a separate test group were compared to the interpretations of independent 
physicians. The skeleton and bone marrow were segmented using a convolutional neural network. 
The training of AI was based on 153 un‑treated patients. Bone uptake significantly higher than the 
mean BMU was marked as abnormal, and an index, based on the total squared abnormal uptake, 
was computed to identify the focal uptake. Patients with an index above a predefined threshold were 
interpreted as having focal uptake. As the test group, 48 un‑treated patients who had undergone a 
staging FDG‑PET/CT between 2017–2018 with biopsy‑proven HL were retrospectively included. Ten 
physicians classified the 48 cases regarding focal skeleton/BMU. The majority of the physicians agreed 
with the AI in 39/48 cases (81%) regarding focal skeleton/bone marrow involvement. Inter‑observer 
agreement between the physicians was moderate, Kappa 0.51 (range 0.25–0.80). An AI‑based method 
can be developed to highlight suspicious focal skeleton/BMU in HL patients staged with FDG‑PET/CT. 
Inter‑observer agreement regarding focal BMU is moderate among nuclear medicine physicians.
Skeleton/bone marrow involvement in patients with newly diagnosed Hodgkin’s lymphoma (HL) is an impor-
tant predictor of adverse  outcomes1. Studies show that FDG-PET/CT upstages patients with uni- or multifocal 
skeleton/bone marrow uptake (BMU) when iliac crest bone marrow biopsy fails to find evidence of histology-
proven  involvement2,3. The general recommendation is, therefore, that bone marrow biopsy can be avoided when 
FDG-PET/CT is performed at  staging4,5.
Classifications of focal skeleton/BMU can sometimes be challenging. Artificial intelligence (AI) is being 
developed to assist the observer by highlighting suspicious uptake in diagnostic  images6. Earlier studies have 
showed that AI can be trained to find suspicious bone involvement and provide the results quantitatively and 
objectively, rather than in a subjective  way7. Other studies show that AI can be of benefit by decreasing inter-
observer variations among physicians and increasing the sensitivity in finding  lesions8.
Sibille et al. recently developed AI-based software for PET/CT  images9. They included a mixture of lung cancer 
and lymphoma patients at different phases (29% during staging, 25% during treatment, and 46% after treatment), 
showing good performance in finding lesions. However, due to the few included newly diagnosed lymphoma 
patients in the test group, it is still unclear how their software performs in the detection of focal skeleton/BMU 
in this specific patient category.
Our aim was to develop an AI-based method for the detection of focal skeleton/BMU and quantification of 
diffuse BMU in patients with HL undergoing staging with FDG-PET/CT. The output of the AI-based method in 
a separate test set was compared to the image interpretation of ten physicians from different hospitals. Finally, 
the AI-based quantification of diffuse BMU was compared to manual quantification.
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Methods
Patients. Training cohort. All 156 patients who had undergone a staging PET/CT between 2011 and 2016 
at Sahlgrenska University Hospital with biopsy-proven HL were retrospectively included. All were newly diag-
nosed and un-treated patients. Two patients were excluded due to incomplete image sets, and one patient was 
excluded due to failed skeletal segmentation. The final group consisted of 153 patients (Table 1). These examina-
tions were used in the development of the AI-based method.
Test cohort. All 49 patients who had undergone staging with FDG-PET/CT between 2017 and 2018 at Sahl-
grenska University Hospital with biopsy-proven HL were retrospectively included. All were newly diagnosed 
and un-treated patients. One patient was excluded due to a falsely reported injection time, and 48 patients were 
evaluated as the test cohort (Table 1). These examinations were used for the testing of the AI-based method and 
for inter-observer classifications.
Image acquisition. PET/CT data were obtained using an integrated PET/CT system (Siemens Biograph 64 
Truepoint). The adult patients were injected with 4 MBq/kg 18F-FDG (maximum 400 MBq) and fasted for at 
least 6 h before the injection of FDG. The injected amount of radioactivity for children was according to the 
EANM Dosage Card (Version 5.7.2016). The standard accumulation time was 60 min. Images were acquired 
with 3 min per bed position from the base of the skull to the mid-thigh. PET images were reconstructed with 
a slice thickness of 5 mm and slice spacing of 3 mm with an iterative OSEM 3D algorithm (4 iterations and 8 
subsets) and matrix size of 168 × 168. CT-based attenuation and scatter corrections were applied. A low-dose CT 
scan (64-slice helical, 120 kV, 30 mAs, 512 × 512 matrix) was obtained covering the same part of the patient as 
the PET scan. The CT was reconstructed using a filtered back-projection algorithm with a slice thickness and 
spacing matching those of the PET  scan10.
Artificial intelligence‑based classification. A convolutional neural network (CNN) was used to seg-
ment the skeletal  anatomy11. Based on this CNN, the bone marrow was defined by excluding the edges from each 
individual bone; more precisely, 7 mm was excluded from the humeri and femora, 5 mm was excluded from the 
vertebrae and hip bones, and 3 mm was excluded from the remaining bones.
Focal skeleton/bone marrow uptake. The basic idea behind our approach is that the distribution of non-focal 
BMU has a light tail and most pixels will have an uptake reasonably close to the average. There will still be vari-
ations between different bones. Most importantly, we found that certain bones were much more likely to have 
diffuse BMU than others. Hence, we cannot use the same threshold for focal uptake in all bones. At the other 
end, treating each bone individually is too susceptible to noise. As a compromise, we chose to divide the bones 
into two groups:
• “spine”—defined as the vertebrae, sacrum, and coccyx as well as regions in the hip bones within 50 mm from 
these locations, i.e., including the sacroiliac joints.
• “other bones”—defined as the humeri, scapulae, clavicles, ribs, sternum, femora, and the remaining parts of 
the hip bones.
For each group, the focal standardized uptake values (SUVs) were quantified using the following steps:
1. Threshold computation. A threshold (THR) was computed using the mean and standard deviation (SD) of 
the SUV inside the bone marrow. The threshold was set to
2. Abnormal bone region. The abnormal bone region was defined in the following way:
  Only the pixels segmented as bone and where SUV > THR were considered. To reduce the issues of PET/
CT misalignment and spill over, a watershed transform was used to assign each of these pixels to a local 
maximum in the PET image. If this maximum was outside the bone mask, the uptake was assumed to be 
leaking into the bone from other tissues and was removed. Finally, uptake regions smaller than 0.1 mL were 
removed.
3. Abnormal bone SUV quantification. The mean squared abnormal uptake (MSAU) was first calculated as
THR = SUVmean + 2SD.
MSAU = mean of (SUV−THR)2 over the abnormal bone region.
Table 1.  Study population.
Training cohort Test cohort
Number of patients 153 48
Female (%) 46 46
Median age (y), range 33, 11–85 35, 7–75
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  To quantify the abnormal uptake, we used the total squared abnormal uptake (TSAU), rather than the more 
common total lesion glycolysis (TLG). We believe TLG tends to overestimate the severity of larger regions 
with moderate uptake. TSAU will assign a much smaller value to such lesions, reflecting the uncertainty 
that is often associated with their classification. Instead, TSAU will give a larger weight to small lesions with 
very high uptake. This reflects both the higher certainty with respect to their classification and the severity 
typically associated to very high uptake.
This calculation leads to two TSAU values; one for the “spine” and one for the “other bones”. As the TSAU 
value can be nonzero even for patients without focal uptake, cut-off values were tuned using the training cohort. 
The AI method was adjusted in the training group to have a positive predictive value of 65% and a negative 
predictive value of 98%. For the “spine”, a cut-off of 0.5 was used, and for the “other bones”, a cut-off of 3.0 was 
used. If one of the TSAU values was higher than the corresponding cut-off, the patient was considered to have 
focal uptake.
Diffuse bone marrow uptake. The  SUVmedian in the vertebral bone marrow was automatically computed and 
compared to the median uptake in the liver. The latter was also segmented using a CNN according  to10. Figure 1 
shows an example. If the ratio between the median “spine” BMU and liver uptake was greater than 1.0, the 
patient was considered to have diffuse  BMU1.
Quality control was performed in the test patients regarding the automated AI calculations of diffuse BMU. 
An experienced technologist manually placed the region of interest (ROI) in the marrow area of lumbar vertebrae 
L3/L4 and at the upper homogenous right part of the liver (excluding the edges). These regions were chosen 
according to the study by Pedersen et al.1.
Image interpretations. Training. The original interpretation of the PET/CT examinations was per-
formed by a nuclear medicine physician and a radiologist, who wrote the final report sent to the referring depart-
ment. A trained technologist extracted information regarding skeleton and/or bone marrow involvement from 
these PET/CT reports and from the digital medical records. All the cases with focal or suspicious focal uptake in 
skeletal and/or bone marrow were reviewed again by a nuclear medicine specialist.
Test. Ten nuclear medicine physicians with 2–12 years of experience in PET/CT working in three different 
hospitals (two in Sweden (Malmö/Lund and Gothenburg) and one in India (Chandigarh)) were invited to par-
ticipate. They separately classified the 48 FDG-PET/CT images regarding diffuse uptake in bone marrow and 
focal uptake in skeletal/bone marrow in the following four  categories1.
– Low diffuse bone marrow uptake and no focal lesion(s)
– Low diffuse bone marrow uptake and focal lesion(s)
– High diffuse bone marrow uptake and no focal lesion(s)
– High diffuse bone marrow uptake and focal lesion(s)
TSAU = MSAU× (volume of the abnormal bone region).
Figure 1.  CT: Example of bone and liver segmentations performed by the artificial intelligence-based method.
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The cases were presented in a different computer-generated randomized order to each physician. Information 
regarding sex, age, and investigations involving untreated staging HL patients was provided. The physicians were 
instructed to classify the cases as they normally do in the clinical setting. The review process was performed using 
RECOMIA software (recomia.org), and every case was presented with CT images, PET images, fused PET/CT 
images, and MIP images. The interpreter was also able to shift between sagittal, coronal and transverse planes. 
The PET images could be displayed in different colours with the images scaled to an upper SUV threshold of 5, 
and the latter could also be changed. The CT images could be shifted to the skeleton window.
The study was approved by the ethics committee at Gothenburg University, and the need for written informed 
consent was waived (#2019–01,274). We certify that the study was performed in accordance with the ethical 
standards laid down in the 1964 Declaration of Helsinki and its later amendments.
Statistical analyses. The percentage agreement (PA) and Kappa were used in the inter-observer comparisons 
between physicians for the classifications of both focal skeletal/BMU and diffuse BMU. Kappa takes into account 
chance agreement, and some suggested interpretation guidelines are as follows; values < 0 indicate no agreement, 
values between 0 and 0.20 indicate slight agreement, values between 0.21 and 0.40 indicate fair agreement, values 
between 0.41 and 0.60 indicate moderate agreement, values between 0.61 and 0.80 indicate substantial agree-
ment, and values between 0.81 and 1 indicate almost perfect  agreement12.
Results
Focal uptake. Fourteen of the 48 cases were classified as having focal skeleton/BMU by the AI-based 
method. The majority of physicians classified 7/48 cases as positive and 41/48 cases as negative for having focal 
skeleton/BMU. The majority of the physicians agreed with the AI method in 39 of the 48 cases. An example can 
be seen in Fig. 2. Six of the seven positive cases (86%) identified by the majority of physicians were identified as 
Figure 2.  FDG-PET/CT: Example of a patient classified as having focal uptake in skeleton/bone marrow by 
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positive by the AI method, while the seventh was classified as negative by the AI method and by three of the ten 
physicians.
Thirty-three of the 41 negative cases (80%) identified by the majority of physicians were also classified as 
negative by the AI method. In seven of the remaining eight patients, 1–3 physicians (out of the ten total) classi-
fied the cases as having focal uptake, while in one of the eight cases none of the physicians classified it as having 
focal uptake. These findings indicate that the AI method has been developed towards high sensitivity, which is 
necessary to highlight suspicious uptake.
The pairwise agreement between the ten physicians resulted in 45 unique pairs. The mean PA was 85% (range 
79–94%), and the mean Kappa was 0.51 (range 0.25–0.80) between the paired physicians, regarding the presence 
or absence of focal skeleton/BMU. Examples of different Kappa values can be found in Tables 2–4.
Diffuse bone marrow uptake. The automatic AI calculations of the SUV index, i.e., the median spine 
marrow uptake/liver, indicated that 32 patients had an index > 1.0 (high diffuse BMU), while 16 patients had an 
index of 1.0 or below (low diffuse BMU). In 33 (69%) cases, most of the physicians agreed with the AI method. 
In one case, half of the physicians agreed with the AI method, and in 14 cases, most of the physicians disagreed 
with the AI method regarding high versus low BMU. These 14 cases were classified as low diffuse BMU by most 
of the physicians (Fig. 3).
The agreement between the ten physicians (45 unique pairs) concerning high versus low diffuse BMU resulted 
in an average PA of 70% (range 21–88%), with a mean Kappa value of 0.41 (range 0.03–0.68).
Figure 4 shows a Bland–Altman plot comparing the AI-automated SUV index calculations versus the manual 
method regarding high or low BMU. The graph indicates that the AI and the manual SUV index calculations 
are relatively comparable except for one outlier. This outlier had focal bone marrow involvement predominantly 
located in L4, why the SUV index with the manual method resulted in a much higher value compared with the 
AI method that takes into account the  SUVmedian value in the whole spine bone marrow. Table 5 shows the larger 
volumes used by the AI method compared with the manual ROI method in the SUV index calculations.
If diffuse BMU is considered a dichotomous variable, i.e., high versus low, then both the AI versus manual 
methods were in concordance with each other in all cases except in one (SUV index 0.9 with the AI method 
versus 1.1 with the manual method).
Table 2.  Frequency table showing the pairs of observers with the lowest Kappa (0.25) regarding the 








Table 3.  Frequency table showing the pairs of observers with the median Kappa (0.54) regarding the 








Table 4.  Frequency table showing the pairs of observers with the highest Kappa (0.80) regarding the 
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Figure 3.  SUV index: (spine marrow uptake/liver) calculated by the artificial intelligence-based method 
compared with the physicians’ majority classifications of diffuse bone marrow uptake.
Figure 4.  Bland–Altman plot: comparison between the SUV index calculated by the artificial intelligence (AI)-
based method versus the manual method.
Table 5.  Volumes used by the artificial intelligence (AI)-based method compared with the manual method for 
the SUV index calculations. ROI = Region of interest.
AI (mL) Manual ROI  (cm3)
Spine bone marrow: median (range) 161 (32–298) 2 (1–3)
Liver: median (range) 1523 (607–2800) 14 (8–28)
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Discussion
The present study demonstrates that an AI-based method can be developed to highlight suspicious focal skel-
eton/BMU in HL patients staged with FDG-PET/CT. This AI-based method can also objectively provide results 
regarding high versus low BMU by calculating the  SUVmedian in the spine marrow and the liver. We have also 
demonstrated that inter-observer variations regarding both focal and diffuse BMU are moderate (mean Kappa 
0.51 and 0.41, respectively) among the group of nuclear medicine physicians with 2–12 years of experience 
working at different hospitals. Finally, our results show that the automated method regarding diffuse BMU is 
comparable to the manual ROI method.
Pedersen et al. emphasize the importance of finding focal bone lesions (uni- or multifocal) since both progres-
sion-free survival rate and overall survival significantly indicate poorer prognosis compared with the non-bone 
lesion  group1. Earlier studies report high inter-observer agreement (Kappa 0.84 and 0.74–0.86, respectively) 
among physicians, which differs from our results (mean Kappa 0.51)13,14. Zwarthoed et al. and Hofman et al. 
included two to three physicians interpreting 180 and 100 patients, respectively. No information was given in 
the former study regarding the experience levels or whether the observers were from the same institution, while 
in the latter study, all the physicians were experienced they seemingly worked at the same hospital. It is known 
that training and continuous discussions among colleagues improve inter-observer  agreement15. The moderate 
agreement found in our study, including ten physicians from different centres interpreting 48 cases, is probably 
more generalizable since not all the physicians interpreting PET/CT were experienced or were working in the 
same institution.
The need to develop an AI-based method is not to replace physicians but rather to help them by taking advan-
tage of the rapid calculations performed by AI. The results showed that the majority of the physicians agreed with 
the AI interpretations regarding focal uptake in 81% (39/48) of the cases but disagreed in nine of the cases. Eight 
of these nine cases were classified as positive by the AI method, and in seven of those 1–3 (of the 10) physicians 
interpreted the images as positive for focal uptake. We felt that it was important to shift the system towards high 
sensitivity to avoid missing suspicious findings. The strength of physicians, on the other hand, is that they can 
dismiss uptake due to benign conditions such as degeneration in the spine or uptake in brown fat adjacent to 
bones; i.e., they have a higher specificity than the AI-based method.
Sibillie et al. developed an automated method for the classification of lung cancer and lymphoma showing 
high performance with an area under the receiver operating characteristic curve of 0.989. However, their included 
patients had, apart from different kinds of cancers, also a mix of different lymphoma types examined at different 
phases (staging, during treatment and after treatment) which makes a direct comparison with our study, which 
focused solely on staging HL patients, difficult. Another limitation in their study was that they used the same 
physicians for the segmentation of lesions both for training, validation, and testing. Therefore, it is likely that 
the classifications tend to agree more between training and testing, and an independent gold standard for the 
test group would be preferable.
Earlier studies revealed that diffusely increased BMU is likely to be reactive/inflammatory, i.e., correlate with 
lower haemoglobin levels and higher leukocyte counts, and should not be considered a risk  factor1,13. It is, how-
ever, a common practice that physicians mention high diffuse BMU in the final report. Pedersen et al. found that 
physicians tend to underestimate high BMU when the visual method is used, i.e., comparing the bone marrow 
with the  liver1. This finding is in concordance with our results, that the most common cause of disagreement 
between the physicians and AI (29%, 14/48 cases) was due to the underestimation of the BMU. Figure 5 shows an 
example. Pedersen et al. recommend that if physicians find it necessary to comment on this task, then the com-
ment should be based on objective calculations of SUV in, for example, L3/L4 and the upper part of the liver. If 
our automated AI calculations were treated as a continuous variable, then the results were relatively comparable 
with the manual ROI method (Figs. 3 and 4), and if treated as a dichotomous variable (high versus low BMU), 
the two methods agreed in all cases except in one.
Before applying this novel AI-based method in the clinical setting, it should be further evaluated in a new 
group of HL patients from other hospitals and examined with other PET/CT devices. The training of the AI 
method is also crucial. We used the final report of the PET/CT examination sent to the refereeing department 
and extracted information regarding bone and bone marrow involvement from the medical record. However, we 
did not define the ground truth for the test group. Instead, the physicians’ interpretations were compared with 
each other resulting in moderate agreement both for focal uptake and with even lower Kappa for diffuse BMU. 
This finding indicates that interpretations of this kind are difficult. Collaborations and further studies with other 
centres providing similar patient material are welcomed.
Achieving equal healthcare is essential; i.e., interpretations of the same diagnostic images should be similar 
independent of the experience of the reporting physicians. Our aim was to develop an AI-based method to 
highlight suspicious focal uptake in skeleton/bone marrow and provide a result for high/low diffused BMU. 
The future goal is to systemize interpretations and minimize inter-observer variations. The AI-based method is 
independent of temporary human tiredness, disturbance, and type of department such as a university hospital 
setting with many colleagues available for discussions or a regional hospital. The next step is to invite the same 
physicians to interpret the same PET/CT images, this time also considering the AI-based suggestions regarding 
focal and diffuse uptake in skeleton/bone marrow.
Even though high BMU should not be considered a risk  factor1,13, the lowest Kappa among paired observers 
was 0.03, i.e., agreement equivalent to chance. Our AI-based method can objectively provide a value that cor-
responds relatively well with the manual ROI method (Fig. 4). An explanation of the difference between the two 
methods could be that the AI method uses the bone marrow volume for the whole spine and the liver, excluding 
the edges, while the manual ROI method is restricted to three slices (two in L3/L4 and one in the liver). Finally, 
we used  SUVmedian instead of  SUVmax to minimize extreme values due to focal lesion uptake.
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Conclusions
The present study demonstrates that an AI-based method can be developed to highlight suspicious focal skeleton/
BMU in HL patients staged with FDG-PET/CT. This AI-based method can also objectively provide results regard-
ing high versus low BMU by calculating the  SUVmedian value in the whole spine marrow and the liver. Additionally, 
the study also demonstrated that inter-observer agreement regarding both focal and diffuse BMU is moderate 
among nuclear medicine physicians with varying levels of experience working at different hospitals. Finally, 
our results show that the automated method regarding diffuse BMU is comparable to the manual ROI method.
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